PIC: Influence of Probiotics on Infections in Cirrhosis
Study Details
Study Description
Brief Summary
Liver cirrhosis is the 10th most common cause of death in the western world. Infection is the most common precipitant of deterioration of liver function in cirrhosis. Endotoxin, derived from gram-negative organisms in the gut, can enter the circulation due to increased gut permeability and contributes to neutrophil dysfunction, infection risk and mortality in alcoholic cirrhotics. As probiotics decrease gram-negative organisms in the gut and/or decrease gut permeability, the investigators hypothesize that probiotic treatment would restore neutrophil function and prevent infection in alcoholic cirrhosis.
The investigators hypothesize that administration of a probiotic mixture in patients with liver cirrhosis will improve innate immune function through alteration of the gut bacterial flora and gut barrier integrity.
The aim of this randomised, double-blinded placebo-controlled study is to assess whether food supplementation with probiotic mixture improves neutrophil phagocytic capacity in patients with cirrhosis and decreases the incidence of significant infections.
92 patients with alcoholic cirrhosis will be included according to a sample size calculation from preliminary data. Patients will be randomized in two groups: Group 1 receives a probiotic mixture Group 2 receives a similar looking and tasting placebo without bacteria. The recruited patients will be treated for 6 months. Besides routine clinical and laboratory assessments, neutrophil function, toll-like receptor expression, endotoxin levels, bacterial DNA, cytokine levels, albumin oxidation, gut permeability and analysis of gut microflora will be performed. Furthermore nutritional status and quality of life will be assessed.
Primary endpoints will be neutrophil phagocytosis. Secondary endpoints will be significant infection, neutrophil oxidative burst, neutrophil toll-like receptor expression, endotoxin levels, bacterial DNA; cytokine levels, albumin oxidation, gut barrier function and bacterial flora, nutritional status and quality of life.
If our hypothesis holds true, probiotics will provide an easily applicable and cost effective method to improve immune function and to prevent infection in liver cirrhosis. It is possible that this can improve survival of patients with liver cirrhosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Probiotic 6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day |
Dietary Supplement: Winclove-849
6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
|
| Placebo Comparator: Placebo A similar looking and tasting powder |
Dietary Supplement: Placebo
A similar looking and tasting powder with no active substances
|
Outcome Measures
Primary Outcome Measures
- Change in neutrophil phagocytic capacity [Change from baseline to 6 months]
Percentage of neutrophil granulocytes showing phagocytosis of FITC (fluorescein isothiocyanate) -labelled E.coli bacteria
Secondary Outcome Measures
- Number of clinically significant infections [during 12 months]
Occurence of infections that require specific treatment and/or hospitalisation during the study period of 12 months
- endotoxin levels [0, 6, 12 months]
Endotoxin in serum (EU/ml)
- neutrophil oxidative burst [0, 6, 12 months]
percentage of neutrophil granulocytes showing oxidative burst with and without stimulation and mean fluorescence activity
- neutrophil toll like receptor expression [0, 6, 12 months]
percentage of neutrophil granulocytes showing TLR (Toll-like receptor) 2, TLR4 or TLR9 expression and mean fluorescence activity
- albumin oxidation [0, 6, 12 months]
oxidative status of albumin in the plasma (percentage of (human mercaptalbumin) HMA, (human non-mercaptalbumin) HNA1 and HNA2)
- inflammatory response [0, 6, 12 months]
elevation of one or more inflammatory markers: C reactive protein (mg/ml), lipopolysaccharide binding protein (ng/ml), soluble CD (cluster of differentiation) 14 (ng/ml)
- bacterial flora [0, 6, 12 months]
isolation of bacterial DNA and sequencing the gut microbiome from stool and duodenal aspirate
- quality of life [0, 6, 12 months]
(short form) SF-36 questionaire
- nutritional status [0,6, 12 months]
subjective global assessment
- changes in gut permeability over time [0, 6, 12 months]
elevated lactulose mannitol ratio, elevated zonulin
Eligibility Criteria
Criteria
Inclusion Criteria: • Patients aged between 18-80 years
-
Clinical and radiological evidence of cirrhosis, and/or biopsy proven liver cirrhosis of any cause
-
Informed consent
Exclusion Criteria:
-
Child-Pugh score > 11
-
Abstinence from alcohol for < 2 weeks at the time of screening for inclusion
-
Clinical evidence of active infection
-
Antibiotic treatment within 7 days prior to enrolment
-
Gastrointestinal haemorrhage within previous 2 weeks
-
Use of immunomodulating agents within previous month (steroids etc.)
-
Use of proton pump inhibitors for preceding two weeks
-
Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the study
-
Renal failure (such as hepatorenal syndrome), creatinine >1.7 mg/dL
-
Hepatic encephalopathy II to IV
-
Pancreatitis
-
Other organ failure
-
Hepatic or extra-hepatic malignancy
-
Pregnancy
-
Presumed non-compliance to the study medication
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Internal Medicine, Medical University of Geraz | Graz | Austria | 8036 |
Sponsors and Collaborators
- Medical University of Graz
- Austrian Science Fund (FWF)
Investigators
- Principal Investigator: Vanessa Stadlbauer-Köllner, MD, Medical University of Graz
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PIC-2010